Clinical Trial

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-29
Trial Details
NCT Number NCT07479485
Lead Sponsor Lepu Biopharma Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 160 participants
Start Date 2026-04-08
Primary Completion 2028-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-28